Strategic Focus Oncology CRO with end-to-end capabilities spanning pre-IND to registration trials presents a full-service outsourcing option for pharma/biotech clients seeking specialized clinical development in cancer.

Targeted Events Recent participation in ASCO GI and SITC meetings signals active engagement with oncology researchers and potential partnership opportunities with sponsors pursuing immunotherapy and GI cancer programs.

Growth Readiness Small team size (2-10 employees) coupled with leadership experience across development lifecycles suggests agility for niche programs, but potential need for scalable capacity to handle larger or multiple concurrent trials.

Digital & Ops Tech stack including iCIMS, WordPress, Shopify, and Microsoft 365 indicates modern recruiting, marketing, and operations capabilities; opportunities exist to leverage digital outreach and customer relationship management for lead generation.

Financial Signals Revenue range of one to ten million dollars implies a growth-stage CRO that could benefit from strategic collaborations, co-development deals, or multi-site trial opportunities to scale revenue and capabilities.